Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients.
Journal
Blood pressure monitoring
ISSN: 1473-5725
Titre abrégé: Blood Press Monit
Pays: England
ID NLM: 9606438
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
pubmed:
11
9
2020
medline:
6
3
2021
entrez:
10
9
2020
Statut:
ppublish
Résumé
Hypertension is a chronic condition leading to increased stress on the heart and blood vessels, a critical risk factor for clinically significant events such as myocardial infarction heart failure, stroke and death. Chlorthalidone and hydrochlorothiazide are first-line antihypertensive agents for most patients with hypertension. The aim of our meta-analysis was to compare the efficacy and safety of both therapies in patients with hypertension. Searches of electronic databases PubMed, MEDLINE, Scopus, PsycInfo and eLIBRARY.ru, were performed. We used network meta-analysis to combine direct and indirect evidence. Forest plots and closed loops depict estimated results from studies included in our meta-analysis. Of 1289 identified sources, only 37 were included in our meta-analysis. Our analysis has demonstrated a slight superiority for chlorthalidone regarding SBP and not statistically significant differences regarding DBP. Simultaneously, hydrochlorothiazide seems to be a safer choice of therapy, as evidenced by the levels of serum potassium. The two diuretics can be used interchangeably.
Identifiants
pubmed: 32909966
pii: 00126097-202104000-00013
doi: 10.1097/MBP.0000000000000486
pmc: PMC7932752
doi:
Substances chimiques
Antihypertensive Agents
0
Diuretics
0
Hydrochlorothiazide
0J48LPH2TH
Chlorthalidone
Q0MQD1073Q
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
160-168Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Public Health Agency of Canada, Background Information: Hypertension. http://www.phac-aspc.gc.ca/cd-mc/cvd-mcv/hypertension-eng.php . [Accessed 8 March 2020].
Daskalopoulou SS, Khan NA, Quinn RR, et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012; 28:270–287.
Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360:1347–1360.
Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple risk factor intervention trial research group. Arch Intern Med. 1992; 152:56–64.
Hutton B, Tetzlaff J, Yazdi F, Thielman J, Kanji S, Fergusson D, et al. Comparative effectiveness of monotherapies and combination therapies for patients with hypertension: protocol for a systematic review with network meta-analyses. Syst Rev. 2013; 2:44.
Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009; 361:2153–2164.
Cranston WI, Juel-Jensen BE, Semmence AM, Jones RP, Forbes JA, Mutch LM. Effects of oral diuretics on raised arterial pressure. Lancet. 1963; 2:966–970.
Saseen JJ, Ghushchyan V, Nair KV. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population. J Clin Hypertens (Greenwich). 2015; 17:134–140.
Kjelsberg MO. Mortality after 10 1/2 years for hypertensive participants in the multiple risk factor intervention trial. Circulation. 1990; 82:1616–1628.
Bhattacharaya M, Alper SL. Pharmacology of volume regulation. Golan DE, Tashjian AH Jr, Armstrong EJ, Armstrong AW, editors. In: Principles of Pharmacology: The pathophysiologic Basis of Drug Therapy. 3rd ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012:332–352.
Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension. 2010; 56:463–470.
Sato K, Dohi Y, Kojima M, Takase H, Suzuki S, Ito S. Antioxidative effects of thiazide diuretics in refractory hypertensive patients. A randomized crossover trial of chlortalidone and trichlormethiazide. Arzneimittelforschung. 2010; 60:612–616.
Collste P, Garle M, Rawlins MD, Sjöqvist F. Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses. Eur J Clin Pharmacol. 1976; 9:319–325.
Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: mechanisms of action and effect on cardiovascular events. Curr Hypertens Rep. 2013; 15:514–521.
Cooney D, Milfred-LaForest S, Rahman M. Diuretics for hypertension: hydrochlorothiazide or chlorthalidone? Cleve Clin J Med. 2015; 82:527–533.
Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998; 12:861–866.
Canter D, Frank GJ, Knapp LE, Phelps M, Quade M, Texter M. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. Quinapril investigator group. J Hum Hypertens. 1994; 8:155–162.
Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med. 1994; 154:737–743.
Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996; 5:17–24; discussion 25.
Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004; 17:252–259.
Edes I; Multicentre Study Group. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Investig. 2009; 29:293–304.
Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med. 1994; 154:1461–1468.
Goldberg MR, Rockhold FW, Offen WW, Dornseif BE. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. Clin Pharmacol Ther. 1989; 46:208–218.
Grimm RH Jr, Black H, Rowen R, Lewin A, Shi H, Ghadanfar M; Amlodipine Study Group. Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. Am J Hypertens. 2002; 15:31–36.
Horie Y, Higaki J, Takeuchi M. Design, statistical analysis and sample size calculation of dose response study of telmisartan and hydrochlorothiazide. Contemp Clin Trials. 2007; 28:647–653.
Hulley SB, Furberg CD, Gurland B, McDonald R, Perry HM, Schnaper HW, et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. Am J Cardiol. 1985; 56:913–920.
Jounela AJ, Lilja M, Lumme J, Mörlin C, Hoyem A, Wessel-Aas T, Borrild NJ. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press. 1994; 3:231–235.
Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999; 12:797–805.
Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens. 1994; 8:283–288.
Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, Morledge J. Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin Pharmacol Ther. 1978; 24:192–198.
Janet B, McGill MD, Paul A, Reilly PhD. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clinical Therapeutics. 2001; 23:833–850.
Morledge JH, Ettinger B, Aranda J, McBarron F, Barra P, Gorwit J, Davidov M. Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone. J Am Geriatr Soc. 1986; 34:199–206.
Papademetriou V, Reif M, Henry D, et al. Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension. J Clinical Hypertension. 2000; 2:372–378.
Papademetriou V, Hainer JW, Sugg J, Munzer D; ATTACH Study Group. Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination Am J Hypertens. 2006; 19:1217–1225.
Pool JL, Cushman WC, Saini RK, Nwachuku CE, Battikha JP. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens. 1997; 10:117–123.
Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007; 29:61–73.
Pordy RC. Cilazapril plus hydrochlorothiazide: improved efficacy without reduced safety in mild to moderate hypertension. A double-blind placebo-controlled multicenter study of factorial design. Cardiology. 1994; 85:311–322.
Scholze J, Breitstadt A, Cairns V, Bauer B, Bender N, Priestley C, et al. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany collaborative trial group. J Hypertens. 1993; 11:217–221.
Vardan S, Mehrotra KG, Mookherjee S, Willsey GA, Gens JD, Green DE. Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. JAMA. 1987; 258:484–488.
Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007; 25:217–226.
Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens. 1992; 6:133–138.
Zachariah PK, Messerli FH, Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment. Clin Ther. 1993; 15:779–787.
Yodfat Y, Zimilchman R. Dose-finding and dose justification of once-daily cilazapril in combination with hydrochlorothiazide in non-obese patients with mild-to-moderate essential hypertension. J Drug Dev. 1994; 6:117–121.
Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012; 125:1229.e1–1229.e10.
Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013; 158:447–455.
Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011; 57:689–694.
Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006; 47:352–358.
Kwon BJ, Jang SW, Choi KY, Kim DB, Cho EJ, Ihm SH, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension. Hypertens Res. 2013; 36:79–84.
Pareek A, Basavanagowdappa H, Zawar S, Kumar A, Chandurkar N. A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. Expert Opin Pharmacother. 2009; 10:1529–1536.
Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, et al. Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol. 2016; 67:379–389.
van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med. 2014; 127:763–771.
Hancock M, Kent P. Interpretation of dichotomous outcomes: risk, odds, risk ratios, odds ratios and number needed to treat. J Physiother. 2016; 62:172–174.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981–2997.
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP cooperative research group. JAMA. 1991; 265:3255–3264.
Tziomalos K, Athyros VG, Mikhailidis DP, Karagiannis A. Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension. Curr Pharm Des. 2013; 19:3766–3772.
Roush GC, Abdelfattah R, Song S, Ernst ME, Sica DA, Kostis JB. Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2018; 20:1507–1515.
Mehta RT, Pareek A, Purkait I. Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison. Clin Hypertens. 2018; 24:4.
Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005; 7:354–356.
Pareek AK, Messerli FH, Chandurkar NB. Reply: efficacy of low-dose chlorthalidone versus hydrochlorothiazide remains ambiguous. J Am Coll Cardiol. 2016; 68:430–431.
Springer K. Chlorthalidone vs. hydrochlorothiazide for treatment of hypertension. Am Fam Physician. 2015; 92:1015–1016.
Vongpatanasin W. Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. Curr Opin Cardiol. 2015; 30:361–365.